The price of Roivant Sciences Ltd (NASDAQ:ROIV) shares last traded on Wall Street rose 2.66% to $11.95.
ROIV stock price is now 1.41% away from the 50-day moving average and 6.94% away from the 200-day moving average. The market capitalization of the company currently stands at $8.84B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 100,000 shares of the company’s stock on Oct 21 ’24. The stock was sold for $1,165,000 at an average price of $11.65. Upon completion of the transaction, the President & COO now directly owns 617,470 shares in the company, valued at $7.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 21 ’24, Officer Venker Eric bought 100,000 shares of the business’s stock. A total of $1,165,393 was incurred on buying the stock at an average price of $11.65. A total of 49.13% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $8.47 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 10.43, and a quick ratio of 10.43. The fifty day moving average price for ROIV is $11.7794 and a two-hundred day moving average price translates $11.1663 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for 2024-09-30. The net profit margin was 3827.42% and return on equity was 159.08% for ROIV. The company reported revenue of $4.47 million for the quarter, compared to $3.65 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.67 percent.
